About this Research Topic
The chronic nature of allergic diseases represents a substantial global healthcare burden. Allergic diseases feature both acute exaggerated episodes and persistent impacts. Ongoing pathophysiological signaling, including fibroblast transitions and extracellular matrix deposition, induces tissue remodeling - a late, progressive consequence requiring further molecular elucidation, particularly since effective and safe treatments remain elusive. Allergy-related immunological pathways in tissues also represent a major concern impacting the translational efficacy of several preclinical models.
This Research Topic identifies and anticipates advances in allergic disease pathogenesis and therapies, emphasizing fibroblast phenotype changes, extracellular matrix deposition, and dynamic tissue remodeling evidenced in preclinical and clinical studies. Valid predictions of novel molecular targets and signaling using molecular pharmacology and bioinformatics approaches are encouraged. Comorbidities in allergic diseases, their effects on immunogenicity and pathophysiology, and implications for therapeutic strategies will be highlighted.
This Research Topic welcomes Original Research, Hypothesis and Theory, Review, Systematic Review, Meta-Analysis, Clinical Trial, and Case Report submissions are welcomed in areas including but not limited to:
- Identifying and predicting new genetic, transcriptomic, and metabolomic biomolecular targets that activate and recruit distinct fibroblast phenotypes and mediate fibroblast-myofibroblast transitions in allergic diseases including but not limited to asthma phenotypes, allergic rhinitis, atopic dermatitis, allergic contact dermatitis, urticaria, angioedema, and allergic conjunctivitis using network pharmacology, bioinformatics, preclinical experiments, and clinical trials.
- Examining tissue variations in extracellular matrix components and deposition and diagnostic criteria related to tissue remodeling in allergic disorders.
- Predicting and elucidating roles of circulating and tissue-resident immune cells including lymphocytes, neutrophils, eosinophils, monocytes, macrophages, basophils,
and mast cells regarding fibroblast-myofibroblast transitions in diverse allergic diseases using network pharmacology, bioinformatics, preclinical experiments, and clinical trials.
- Developing valid and reliable experimental preclinical models of fibroblast-myofibroblast transition-associated allergic disorders including in silico, cell culture, ex vivo, and in vivo techniques.
- Discovering and evaluating preventative and therapeutic modalities, including repurposed targets, that regulate fibroblast-myofibroblast transitions in different allergic diseases through preclinical and clinical trials.
This Research Topic identifies and anticipates advances in allergic disease pathogenesis and therapies, emphasizing fibroblast phenotype changes, extracellular matrix deposition, and dynamic tissue remodeling evidenced in preclinical and clinical studies. Valid predictions of novel molecular targets and signaling using molecular pharmacology and bioinformatics approaches are encouraged. Comorbidities in allergic diseases, their effects on immunogenicity and pathophysiology, and implications for therapeutic strategies will be highlighted.
This Research Topic welcomes Original Research, Hypothesis and Theory, Review, Systematic Review, Meta-Analysis, Clinical Trial, and Case Report submissions are welcomed in areas including but not limited to:
- Identifying and predicting new genetic, transcriptomic, and metabolomic biomolecular targets that activate and recruit distinct fibroblast phenotypes and mediate fibroblast-myofibroblast transitions in allergic diseases including but not limited to asthma phenotypes, allergic rhinitis, atopic dermatitis, allergic contact dermatitis, urticaria, angioedema, and allergic conjunctivitis using network pharmacology, bioinformatics, preclinical experiments, and clinical trials.
- Examining tissue variations in extracellular matrix components and deposition and diagnostic criteria related to tissue remodeling in allergic disorders.
- Predicting and elucidating roles of circulating and tissue-resident immune cells including lymphocytes, neutrophils, eosinophils, monocytes, macrophages, basophils,
and mast cells regarding fibroblast-myofibroblast transitions in diverse allergic diseases using network pharmacology, bioinformatics, preclinical experiments, and clinical trials.
- Developing valid and reliable experimental preclinical models of fibroblast-myofibroblast transition-associated allergic disorders including in silico, cell culture, ex vivo, and in vivo techniques.
- Discovering and evaluating preventative and therapeutic modalities, including repurposed targets, that regulate fibroblast-myofibroblast transitions in different allergic diseases through preclinical and clinical trials.
Keywords: Allergic asthma, Allergic skin diseases, Bioinformatics, Clinical Trials, Extracellular matrix, Fibroblast-myofibroblasts transition, Fibroblasts phenotypes, Pharmacology network, Preclinical models, Tissue remodelling.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
